Research Focus

Gut & GI Research

A research overview of peptides targeting gut barrier integrity, intestinal inflammation, GI motility, and mucosal repair — from BPC-157 tight junction restoration to GLP-1 gut-brain axis modulation.

Research context only. All compounds listed are for laboratory research purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations.

Research FocusGut & GI

Gut & GILiver

For laboratory research only

All Research Systems →

Background

GI Research Context

Gut Barrier Integrity & Leaky Gut

The intestinal epithelium is a single-cell-layer barrier separating the gut lumen from systemic circulation. Tight junction disruption drives systemic inflammation, autoimmunity, and metabolic disease. Multiple peptides restore tight junction protein expression.

GLP-1 & Gut-Brain Axis

GLP-1 is produced by L-cells in the distal gut and acts on the vagus nerve and hypothalamus to regulate appetite, gastric emptying, and glucose metabolism. GLP-1 agonists are among the most studied gut-derived peptide systems.

Intestinal Inflammation & IBD

Inflammatory bowel disease involves dysregulated NF-κB activation, cytokine release, and mucosal immune dysfunction. Anti-inflammatory peptides targeting MC1R and NF-κB show protective effects in colitis models.

Gut Microbiome & Peptide Interactions

The gut microbiome modulates peptide bioavailability and metabolizes certain peptides into bioactive fragments. Microbiome diversity supports GLP-1 secretion and short-chain fatty acid production, which in turn supports gut barrier function.

Compounds

Peptides Targeting Gut & GI Health

Recovery

BPC-157

Gastric pentadecapeptide; heals gastric ulcers and intestinal fistulas; restores tight junction proteins; anti-inflammatory via NF-κB inhibition; promotes angiogenesis in GI tissue.

Key finding: Heals gastric ulcers, intestinal fistulas, and restores tight junction integrity (Sikiric 2018)

Anti-Inflammatory

KPV

Alpha-MSH tripeptide; MC1R-mediated NF-κB inhibition in intestinal epithelium; reduces colitis severity; oral bioavailability studied in IBD models.

Key finding: MC1R-mediated NF-κB inhibition reduces colitis severity in DSS and TNBS models (Dalmasso 2008)

Weight Management

Semaglutide

GLP-1 receptor agonist; slows gastric emptying; reduces appetite via vagal and hypothalamic signaling; anti-inflammatory in gut tissue; studied in NASH/NAFLD.

Key finding: GLP-1 receptor activation reduces hepatic steatosis and gut inflammation; NASH trial data (Newsome 2021)

Weight Management

Tirzepatide

Dual GLP-1/GIP agonism; superior gastric emptying modulation; reduces hepatic fat; anti-inflammatory in metabolic GI disease.

Key finding: Dual agonism produces superior NASH resolution vs semaglutide in Phase 2 data

Antioxidant

Glutathione

Primary intestinal antioxidant; protects against oxidative mucosal damage; supports tight junction integrity; reduces intestinal permeability in oxidative stress models.

Key finding: Glutathione depletion increases intestinal permeability; repletion restores barrier function

Longevity

NAD+

PARP-mediated DNA repair in intestinal epithelium; sirtuin activation reduces gut aging; NAD+ supports enterocyte mitochondrial function and proliferation.

Key finding: NAD+ repletion supports intestinal epithelial cell proliferation and mitochondrial function

Weight Management

RETA3

Triple GLP-1/GIP/glucagon agonism; glucagon receptor activation increases hepatic energy expenditure; studied in NASH and metabolic liver disease.

Key finding: Triple agonism produces superior hepatic fat reduction and metabolic GI improvement in Phase 2

Weight Management

Cagrilintide

Amylin receptor agonist; slows gastric emptying synergistically with GLP-1; reduces food intake via hypothalamic and gut-brain axis signaling.

Key finding: Amylin/GLP-1 co-agonism produces superior gastric emptying modulation and appetite reduction

Skin & Repair

GHK-Cu

Promotes intestinal tissue repair via VEGF upregulation; anti-fibrotic in gut tissue; modulates TGF-β to reduce intestinal fibrosis in IBD models.

Key finding: VEGF-driven intestinal repair and TGF-β modulation reduces gut fibrosis

Recovery

TB-500

Thymosin β4 promotes intestinal progenitor cell mobilization; anti-inflammatory in gut tissue; supports mucosal repair after injury.

Key finding: Intestinal progenitor cell mobilization and anti-inflammatory effects in gut injury models

Mechanisms

GI Research Pathways

Gut Barrier Restoration

Tight junction disruption is the central mechanism of intestinal permeability. BPC-157 and Glutathione restore tight junction proteins (occludin, claudin-1) and reduce paracellular permeability in multiple models.

BPC-157GlutathioneTB-500

NF-κB Anti-Inflammatory (IBD)

NF-κB drives mucosal inflammation in IBD. KPV and BPC-157 inhibit NF-κB through MC1R and NO-dependent pathways respectively, reducing cytokine release and mucosal immune activation.

KPVBPC-157GHK-Cu

GLP-1 / Gut-Brain Axis

GLP-1 receptor agonists modulate gastric emptying, appetite, and hepatic metabolism through vagal and hypothalamic signaling. They also reduce gut inflammation and hepatic steatosis in metabolic liver disease.

SemaglutideTirzepatideRETA3Cagrilintide

Mitochondrial & NAD+ Support

Intestinal epithelial cells have high metabolic demand. NAD+ depletion impairs enterocyte proliferation and barrier function. NAD+ repletion supports mitochondrial function and gut epithelial renewal.

NAD+MOTS-c

Literature

Key Studies in GI Research

Sikiric et al. (2018)Curr Pharm Des

BPC-157 Gut Barrier and Ulcer Healing

BPC-157 healed gastric ulcers, intestinal fistulas, and restored tight junction protein expression in multiple GI injury models, with anti-inflammatory effects via NF-κB inhibition.

Dalmasso et al. (2008)J Clin Invest

KPV Reduces Colitis via MC1R

KPV reduced colitis severity in DSS and TNBS models via MC1R-mediated NF-κB inhibition in intestinal epithelium, with oral bioavailability demonstrated in IBD models.

Newsome et al. (2021)N Engl J Med

Semaglutide in Non-Alcoholic Steatohepatitis

Semaglutide produced NASH resolution without worsening fibrosis in 59% of patients vs 17% placebo, establishing GLP-1 receptor agonism as a key mechanism in metabolic liver disease.

Loomba et al. (2023)N Engl J Med

Tirzepatide in NASH

Tirzepatide produced superior hepatic fat reduction and NASH resolution compared to semaglutide in Phase 2 data, driven by dual GLP-1/GIP agonism and superior weight loss.

Explore These Compounds

Browse the full catalog of research peptides available from SwissNova Labs.

View All Products Back to Research Hub